Download PDF
Thromb Haemost 1974; 31(02): 245-264
DOI: 10.1055/s-0038-1649159
Original Article
Schattauer GmbH

Abnormalities in Clotting and Thrombolysis as a Risk Factor for Stroke

L. O Pilgeram
1   Coagulation Laboratory, Departments of Neurology and Physiology, Baylor College of Medicine, and the Baylor-Methodist Center for Cerebrovascular Research, Houston, Texas
› Author Affiliations
Further Information

Publication History

Received 02 February 1974

Accepted 03 February 1974

Publication Date:
29 June 2018 (online)

    Permissions and Reprints

Summary

Four hundred and six patients with ischemic thrombotic cerebrovascular disease (ITCVD) and 115 age-matched controls were studied to select risk factors which would identify ITCVD-prone individuals from a healthy population. The following factors were evaluated : soluble fibrin, plasminogen, plasminogen activator, fibrinogen, partial thromboplastin time, generation of thromboplastin, fibrin degradation products, triglycerides, type IV lipoproteinemia, and cholesterol. Discriminate function analyses were used to select those risk factors which best separate and classify the ITCVD and control subjects. The primary risk factors are the activated partial thromboplastin time, soluble fibrin, fibrinogen, and plasminogen activator. Utilizing only these four primary risk factors in a discriminate function, 93.2% of the patients were correctly classified. Consideration of other variables increased still further the dis-criminate function.

 

  • References

  • 1 Aggeler P. M, Kosmin M. Anticoagulation prophylaxis and treatment of venous thromboembolic disease. Thrombosis—National Academy of Sciences. 1969: 639
    Google Scholar
  • 2 Alkjaersig N, Fletcher A. P, Sherry S. E-Aminocaproic acid: an inhibitor of plasminogen activation. Journal of Biological Chemistry 1959; 234: 832
    PubMedGoogle Scholar
  • 3 Chaeytan C, Purtilo D. Glomerular capillary thrombosis and acute renal failure after E-Aminocaproic acid therapy. New England Journal of Medicine 1969; 280: 1102
    CrossrefPubMedGoogle Scholar
  • 4 Douglas A. S. 1969; Anticoagulant therapy in coronary artery disease. Thrombosis-National Academy of Sciences 690
    PubMedGoogle Scholar
  • 5 Fearnley G. R. Measurement of spontaneous fibrinolytic activity. Journal of Clinical Pathology 1964; 17: 307
    CrossrefPubMedGoogle Scholar
  • 6 Fearnley G. R. 1970; Fibrinolysis and its pharmacological enhancement in occlusive vascular disease. Advances in Cardiology 4: 211
    PubMedGoogle Scholar
  • 7 Gibinski K. Atherosclerose et coagulation. Revue Francaise d’études Cliniques et Biologiques 1966; 11: 185
    PubMedGoogle Scholar
  • 8 Hampton J. W, Mantooth J, Brandt E. N, Wolf Jr S. G. 1966; Plasma fibrinogen patterns in patients with coronary atherosclerosis. Circulation 34: 1098
    CrossrefPubMedGoogle Scholar
  • 9 Hensen A, Kroes F, van Dyke L, Fekkes N, Hemker H, Loeliger E. A. A double blind study of phenprocoumon prophylaxis after a myocardial infarction. Thrombosis et Diathesis Haemorrhagica 1966; suppl 21: 333
    PubMedGoogle Scholar
  • 10 Kessler G, Lederer H. Fluorometic measurements of triglycerides. Analytical Chemistry. Technicon Symposium. M. I., N. Y. 1965
    Google Scholar
  • 11 Kipshidze N. N, Tordiya M. B, Dzhavakhishvili N. N. Changes in the blood system in longevity. Federation Proceedings (Abstract) 1964; 23: 1247
    PubMedGoogle Scholar
  • 12 Kisker C. D, Rush R. Detection of intravascular coagulation. Journal of Clinical Investigation 1971; 50: 2235
    CrossrefPubMedGoogle Scholar
  • 13 Loewy A. G, Dunathan K, Kriel R, Woleinger Jr H. L. 1961; Fibrinase: Purification of substrate and enzyme. Journal of Biological Chemistry 236: 2625
    PubMedGoogle Scholar
  • 14 Merskey C. G, Kleiner J, Johnson A.J. Quantitative estimation of split products of fibrinogen in human serum: relation to diagnosis and treatment. Blood 28: 1
    PubMedGoogle Scholar
  • 15 Merskey C, Johnson A. J. 1966; Diagnosis and treatment of intravascular coagulation. Thrombosis et Diathesis Haemorrhagica 1966; supp 21: 555
    PubMedGoogle Scholar
  • 16 Mertens B. F, McDuffie F. C, Bowie J. W, Owen Jr. C. A. Rapid sensitive method for measuring fibrinogen split products in human serum. Mayo Clinic Proceedings 1969; 44: 114
    PubMedGoogle Scholar
  • 17 Murphy E. A, Mustard J. F. 1962; Coagulation test and platelet economy in atherosclerotic and control subjects. Circulation 25: 114
    CrossrefPubMedGoogle Scholar
  • 18 Niewiarowski S, Wolosowicz N. The In-Vivo effect of E-Aminocaproic acid on the human plasma fibrinolytic system. Thrombosis et Diathesis Haemorrhagica 1966; 15: 491
    PubMedGoogle Scholar
  • 19 Owen Jr. C. A, Didisheim P, Thompson Jr. J. H, Spittel Jr. J.A. Factor VIII and TGA types of hypercoagulability. Thrombosis -National Academy of Sciences. 1969: 573
    Google Scholar
  • 20 Pascuzzi C. A, Spittel Jr. J, Thompson Jr. J. H, Owen Jr. C. A. Thromboplastin generation accelerator. a newly recognized component of the blood coagulation mechanism present in excess in certain thrombotic states. Journal of Clinical Investigation 1961; 40: 1006
    PubMedGoogle Scholar
  • 21 Penick G. D. Blood states that predispose to thrombosis. Thrombosis-National Academy of Sciences. 1969: 553
    Google Scholar
  • 22 Penick G. D, Dejanov I. I, Roberts H. R, Webster W. P. Elevation of factor VIII in hypercoagulable states. In Koller F. (Ed.) Diffuse Intravascular Clotting: F. K. Schattauer (Stuttg.); 1965: 39
    Google Scholar
  • 23 Pilgeram L. O. 1961; The relation of plasma fibrinogen concentration changes to human atherosclerosis. Journal of Applied Physiology 16: 660
    CrossrefPubMedGoogle Scholar
  • 24 Pilgeram L. O. Turnover rate of autologous plasma fibrinogen 14C in subjects with coronary thrombosis. Thrombosis et Diathesis Haemorrhagica 1968; 20: 31
    PubMedGoogle Scholar
  • 25 Pilgeram L. O, Amundson B, Lofgren P. E. Evidence for steroid control of the metabolism of Profibrinolysin. Thrombosis et Diathesis Haemorrhagica 1964; 11: 94
    PubMedGoogle Scholar
  • 26 Pilgeram L. O, Commers L. R. Oxalate induced correction of the plasma antithromboplastin deficiency in the aging arteriosclerotic subject. Thrombosis et Diathesis Haemorrhagica 1964; 10: 350
    PubMedGoogle Scholar
  • 27 Pilgeram L. O, Pickart L. R. Control of fibrinogen biosynthesis: The role of the free fatty acid. Journal of Atherosclerosis Research 1968; 8: 155-166.
    CrossrefPubMedGoogle Scholar
  • 28 Pilgeram L. O, SchrAm A. C. Correlation of activity changes in blood coagulation factors with human arteriosclerosis. Circulation (Abstract) 1959; 20: 991
    PubMedGoogle Scholar
  • 29 Pilgeram L. O, SchrAm A. C, Loegering D. A. Elevation of plasma antithrombin in the aging arteriosclerotic subject. Journal of Applied Physiology 1963; 18: 329
    CrossrefPubMedGoogle Scholar
  • 30 Pilgeram L. O, SchrAm A. C, Mills D. Specificity of plasma fibrinogen changes in arterosclerosis. Circulation (Abstract) 1960; 22: 668
    PubMedGoogle Scholar
  • 31 Procedure N 24a. Auto Analyzer Manual. Chauncey. New York: Technicon Instruments.; 1964
    Google Scholar
  • 32 Proctor R. R, Rapaport S. I. The partial thromboplastin time with Kaolin. American Journal of Clinical Pathology 1961; 36: 212
    CrossrefPubMedGoogle Scholar
  • 33 Remue W. Thromboseprophylaxe bei kardialer Dekompensation. Medizinische Monatsschrift 1961; 15: 380
    PubMedGoogle Scholar
  • 34 Schmid H. J, Jackson D. P, Conley C. L. Mechanism of action of thrombin on platelets. Journal of Clinical Investigation 1961; 41: 543
    PubMedGoogle Scholar
  • 35 Spittel J. A, Pacuzzi C. A, Thompson J. H, Owen Jr. C. A. Acceleration of early stages of coagulation in certain patients with occlusive arterial or venous diseases : Use of a modified thromboplastin generation test to evaluate clot acceleration. Proceedings of the Mayo Clinic 1960; 35: 37
    PubMedGoogle Scholar
  • 36 Steinmann B. Über Beziehungen zwischen Cholesterin- und Fibrinogen-Gehalt. Thromboembolien und Atherosklerose. Gerontología 1965; 10: 100
    PubMedGoogle Scholar
  • 37 World Health Organization 1970; 43: 891
    PubMed
  • 38 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products in renal venous blood in dog. Thrombosis et Diathesis Haemorrhagica 1964; 12: 87
    PubMedGoogle Scholar